logo

Clinical Trial Calendar

Share
Results Date
Company Name
Ticker
Event
Indication
Outcome
Details
Q2 2019
Celsion Corp.
Data from 1st interim efficacy results from phase III study of ThermoDox (OPTIMA)
primary liver cancer
Q2 2019
Heat Biologics Inc.
Interim data from ComPACT trial of HS-130
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Heat Biologics Inc.
Final data from Phase II readout of HS-110
Non Small Cell Lung Cancer (NSCLC)
Q2 2019
Arbutus Biopharma Corp.
Top line results from phase I trial of AB-506
Hepatitis B Virus (HBV)
Q2 2019
Myovant Sciences Ltd
Top-line data from 1st phase III trials of Relugolix (LIBERTY 1)
Heavy menstrual bleeding associated with uterine fibroids in Women
Q2 2019
CTI BioPharma Corp.
Full top-line data from ongoing phase II study of Pacritinib (PAC203)
Myelofibrosis
Q2 2019
Aerpio Pharmaceuticals, Inc.
Top-line data from phase II study of AKB-9778 (TIME-2b)
Non-proliferative diabetic retinopathy
Early Apr 2019
Dermira Inc.
Topline efficacy and safety results from dose-ranging study of Lebrikizumab
Moderate-to-severe atopic dermatitis
Q2 2019
Corvis Corp
Resubmission of NDA for Brinavess
Rapid conversion of recent onset atrial fibrillation
Q2 2019
Provention Bio, Inc.
Top-line data from phase 1b clinical trial of PRV-300 (PULSE)
Moderate-to-severe ulcerative colitis
Q2 2019
Tiziana Life Sciences PLC
Topline data from phase IIa clinical trial of Milciclib
Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Q2 2019
Arbutus Biopharma Corp.
Top-line results from phase 1a/1b clinical trial of AB-506
Hepatitis B Virus (HBV)
28-Feb-2019
Heat Biologics Inc.
New interim data from ongoing phase II trial of HS-110 plus with Opdivo combination
Advanced non-small cell lung cancer (NSCLC)
15-Feb-2019
Bausch Health Companies Inc.
BHC, BHC.TO
Resubmission of NDA for DUOBRII Lotion
Topical treatment of plaque psoriasis
07-Feb-2019
Sangamo Biosciences Inc
Data from Preliminary safety and biochemical changes at up to 4 weeks from Phase 1/2 clinical trial of SB-318
Mucopolysaccharidosis Type I or MPS I in adults
07-Feb-2019
Sangamo Biosciences Inc
Update on safety and biochemical changes at up to 24 weeks from Phase 1/2 clinical trial of SB-913 (CHAMPIONS)
Mucopolysaccharidosis Type II or MPS II in adults
Feb 2019
SCYNEXIS, Inc.
Top-line data from phase III study of SCY-078 (FURI)
Refractory or intolerant fungal diseases
Feb 2019
Cara Therapeutics Inc.
Preliminary results from pivotal phase III trial of KORSUVA injection (KALM-1)
Hemodialysis patients suffering from moderate-to-severe chronic kidney disease-associated pruritus
18-Jan-2019
TYME TECHNOLOGIES, INC.
Interim data from Stage 1 of phase II trial of SM-88
Pancreatic cancer
18-Jan-2019
ASLAN Pharmaceuticals
New safety and efficacy data from its ongoing multicentre phase Ib/II study of Varlitinib plus gemcitabine and cisplatin
First-line biliary tract cancer
18-Jan-2019
Rexahn Pharmaceuticals inc.
Updated data from phase II study of RX-3117 in combination with Abraxane
Newly diagnosed metastatic pancreatic cancer
18-Jan-2019
Rafael Holdings, Inc.
Study plan for phase III trial of Devimistat with modified FOLFIRINOX
First-line treatment for patients with metastatic pancreatic cancer
03-Jan-2019
Sesen Bio Inc
6-month data from phase III trial of Vicinium (VISTA)
High grade non-muscle invasive bladder cancer (NMIBC)
after Q1 2019
BioXcel Therapeutics, Inc.
Top-line data from phase I single dose, dose-escalation study of BXCL501
Acute Treatment of Agitation
2019
Akcea Therapeutics Inc.
Top-line data from phase II program of AKCEA-ANGPTL3-LRx
Hypertriglyceridemia